InsidersTradesSigma
Track the argenx SE stock price and the full management transaction log of the company, a listed issuer based in Netherlands. Shares trade on the NL market, under the authority of AFM. Operating in the Healthcare & Pharma sector, argenx SE has logged 274 reports. Market capitalisation: €63.6bn. The latest transaction was filed on 28 August 2026 (Other). Among the most active insiders: T.J.M. van Hauwermeiren. Every trade is openly available.
274
Insider Decl.
n/a
Thresholds
€4m
70 ops.
Buy Volume
€36m
57 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate argenx SE Strong Buy (bullish), based on 23 analysts. Average price target: US$1,175.61.
27Σ signal
Fundamental score
Ranked 8,574 of 29,055 companies
61.7
score / 100
Value31
Quality93
FCF yld0.9%
Earn yld2.0%
EV/EBITDA48.6x
ROE24%
Gross mgn89%
Net mgn31%
Debt/EBITDA0.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 28 August 2026
Declarations274 total
0@ €385.4237PersoneelsoptieAFM:199431
0@ €302.50670.0010% mcap2.9% of flowPersoneelsoptieAFM:198926
3,555 shares@ €290.00850.0079% mcap20.8% of flowPersoneelsoptieAFM:197727
-110 shares0Restricted Stock UnitAFM:196555
-87 shares0Restricted Stock UnitAFM:196567
-87 shares0Restricted Stock UnitAFM:196556
-110 shares0Restricted Stock UnitAFM:196563
-44 shares0Restricted Stock UnitAFM:196579
00Restricted Stock UnitAFM:196324
-703 shares0Restricted Stock UnitAFM:196325
-703 shares0Restricted Stock UnitAFM:196327
-703 shares0Restricted Stock UnitAFM:196330
-703 shares0Restricted Stock UnitAFM:196329
-703 shares0Restricted Stock UnitAFM:196332
-703 shares0Restricted Stock UnitAFM:196331
-9,847 shares0Restricted Stock UnitAFM:193107
-132 shares0Restricted Stock UnitAFM:191191
-107 shares@ €660.3923.2% of flowGewoon aandeelAFM:188922
25 of 274 declarations
Acerca de argenx SE
argenx SE es una empresa biofarmacéutica centrada en el desarrollo de anticuerpos terapéuticos para el tratamiento de enfermedades autoinmunes y cánceres. Cotiza en el mercado Euronext Ámsterdam.
